>Nordamerikanischer und europäischer Markt für Frauengesundheit, nach Behandlung (Medikamente und Geräte), Indikation (Krebs, reproduktive Gesundheit, urologische Erkrankungen, Schilddrüsenunterfunktion, Postmenopausales Syndrom und andere), Verabreichungsmodus (verschreibungspflichtig und rezeptfrei), Medikamententyp (Marken- und Generika), Pflegetyp (allgemeine Gesundheitspflege und Wellness, Schwangerschafts- und Stillpflege, Becken- und Gebärmutterpflege und andere), Endbenutzer (Krankenhäuser und Kliniken, gynäkologische Zentren, häusliche Pflegeeinrichtungen, Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibungen, Einzelhandelsverkäufe, Online-Verkäufe und andere) – Branchentrends und Prognose bis 2031.
Analyse und Größe des Frauengesundheitsmarktes in Nordamerika und Europa
Die steigende Zahl chronischer Krankheiten bei Frauen sowie sich ändernde Lebensstile und Umweltfaktoren, die sich auf die Gesundheit auswirken, sind einige der Faktoren, die die Nachfrage auf dem Markt ankurbeln. Auch die staatlichen Initiativen zur Verbesserung der allgemeinen Gesundheit und des Wohlbefindens treiben das Marktwachstum weiter voran. Die größte Einschränkung, die den Markt beeinflusst, sind die Nebenwirkungen, die mit bestimmten Produkten verbunden sind. Das zunehmende Bewusstsein und die Akzeptanz von Fruchtbarkeitsbehandlungen bieten eine Chance für das Marktwachstum. Die hohe Müttersterblichkeit und -morbidität stellt eine Herausforderung für das Marktwachstum dar.
Der nordamerikanische und europäische Markt für Frauengesundheit wird voraussichtlich von 9,12 Milliarden US-Dollar im Jahr 2023 auf 16,49 Milliarden US-Dollar im Jahr 2031 anwachsen und im Prognosezeitraum von 2024 bis 2031 eine durchschnittliche jährliche Wachstumsrate (CAGR) von 8,0 % aufweisen.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2024 bis 2031 |
|
Basisjahr |
2023 |
|
Historische Jahre |
2022 (anpassbar auf 2016–2021) |
|
Quantitative Einheiten |
Umsatz in Milliarden USD |
|
Abgedeckte Segmente |
Behandlung (Medikamente und Geräte), Indikation (Krebs, reproduktive Gesundheit, urologische Erkrankungen, Schilddrüsenunterfunktion, Postmenopausales Syndrom und andere), Verabreichungsmodus (verschreibungspflichtig und rezeptfrei), Medikamententyp (Marken- und Generika), Pflegetyp (allgemeine Gesundheitspflege und Wellness, Schwangerschafts- und Stillzeit, Becken- und Gebärmutterpflege und andere), Endnutzer (Krankenhäuser und Kliniken, gynäkologische Zentren, häusliche Pflegeeinrichtungen, Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibungen, Einzelhandelsverkäufe, Online-Verkäufe und andere) |
|
Abgedeckte Länder |
USA, Kanada, Mexiko, Deutschland, Frankreich, Italien, Spanien, Schweiz, Niederlande, Belgien, Russland, Türkei, Großbritannien und Rest von Europa |
|
Abgedeckte Marktteilnehmer |
Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc. und Pfizer Inc. unter anderem |
Marktdefinition
Der Bereich der Medizin und Gesundheitsversorgung, der als „Frauengesundheit“ bekannt ist, widmet sich den besonderen biologischen, physiologischen und psychologischen Anforderungen und Problemen, die Frauen in allen Lebensphasen betreffen. Er deckt eine Reihe von Themen im Zusammenhang mit frauenspezifischer Gesundheitsförderung, gynäkologischer Versorgung, reproduktiver Gesundheit und sexueller Gesundheit ab. Auch geschlechtsspezifische Gesundheitsprobleme im Zusammenhang mit Menstruation, Empfängnisverhütung, Schwangerschaft, Geburt, Menopause und Krankheiten wie Osteoporose, Endometriose , Brustkrebs und Eierstockkrebs fallen unter die Frauengesundheit. Die Frauengesundheit legt auch großen Wert auf Screenings, Vorsorgeuntersuchungen und Interventionen, die darauf abzielen, die geschlechtsspezifischen Unterschiede bei den Ergebnissen, dem Zugang und der Qualität der Gesundheitsversorgung zu schließen.
Marktdynamik für Frauengesundheit in Nordamerika und Europa
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Herausforderungen und Einschränkungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Steigende Zahl chronischer Krankheiten bei Frauen
Die alternde Bevölkerung ist ein wesentlicher Faktor, der zur steigenden Zahl chronischer Krankheiten bei Frauen in Nordamerika und Europa beiträgt. Frauen sind häufiger als Männer von altersbedingten Krankheiten wie Diabetes, Osteoporose, Herz-Kreislauf-Erkrankungen und einigen Krebsarten betroffen. Die zunehmende Zahl frauenspezifischer Erkrankungen treibt die Nachfrage nach neuen Diagnosetechniken, Therapieansätzen und Präventionsmaßnahmen in die Höhe, die auf eine frühzeitige Erkennung, wirksame Behandlung und günstige Ergebnisse abzielen. Gesundheitsdienstleister, Pharmaunternehmen und Hersteller medizinischer Geräte reagieren auf diesen Bedarf, indem sie ihre Investitionen in Forschung und Entwicklung erhöhen, um den sich ändernden Anforderungen von Frauen besser gerecht zu werden. Dies geschieht durch die Ausweitung ihres Produktangebots und die Verbesserung der Modelle der Gesundheitsversorgung.
Um die Auswirkungen chronischer Krankheiten auf die Gesundheit von Frauen in Nordamerika und Europa zu mildern, sind öffentliche Gesundheitsmaßnahmen erforderlich, die sich mit den sozialen Determinanten der Gesundheit befassen, den Zugang zu Gesundheitsdiensten verbessern und gesunde Verhaltensweisen fördern. Gesundheitseinrichtungen, Gesetzgeber, Forscher und Gemeinden müssen zusammenarbeiten, um Krankheiten wie Osteoporose, Endometriose, Brustkrebs und Eierstockkrebs zu bekämpfen, die Frauen weltweit weiterhin betreffen. Daher ist die steigende Zahl chronischer, schwächender Krankheiten bei Frauen ein wichtiger Treiber für das Marktwachstum.
- Entwicklung innovativer Technologien als Folge von Forschungs- und Entwicklungsaktivitäten
Der Bereich der Frauengesundheit verändert sich aufgrund revolutionärer Entwicklungen in der Medizintechnik, die innovative Lösungen für die Diagnose, Behandlung und Bewältigung einer Vielzahl von Erkrankungen bieten. Diese Entwicklungen decken ein breites Spektrum an Technologien ab, wie z. B. zielgerichtete Medikamente, minimalinvasive chirurgische Methoden, Präzisionsmedizin und Strategien der regenerativen Medizin.
Die Nachfrage nach spezialisierten Gesundheitsdienstleistungen, die Zusammenarbeit zwischen Gesundheitsdienstleistern, Wissenschaftlern und Technologieentwicklern sowie Investitionen in die Infrastruktur und die Entwicklung der Belegschaft werden durch die Akzeptanz dieser neuen Behandlungsmethoden angekurbelt.
Die Einbindung digitaler Gesundheitstechnologien, darunter mobile Gesundheits-Apps, Telemedizin und Fernüberwachung, verbessert den Zugang zur Gesundheitsversorgung und ermöglicht es Frauen, eine aktive Rolle im Gesundheitswesen zu übernehmen. Infolgedessen wächst der Markt für Frauengesundheit schnell und ist in ganz Nordamerika und Europa innovativ. Neue Technologien ermöglichen Fortschritte bei den Patientenergebnissen, der Behandlungsqualität und der Gesundheitsversorgung insgesamt. Somit treiben die innovativen Technologien, die als Folge von F&E-Aktivitäten entwickelt werden, das Marktwachstum voran.
Gelegenheit
- Zunehmende Anerkennung für psychische Gesundheit
Psychische Gesundheitsprobleme wie Depressionen, Angstzustände, postnatale Depressionen und Essstörungen betreffen überproportional viele Frauen, oft aufgrund einer Kombination aus biologischen, psychologischen und sozialen Faktoren. Dieses gesteigerte Bewusstsein für psychische Gesundheitsprobleme hat die Nachfrage nach innovativen Therapien, digitalen Tools für die psychische Gesundheit und Unterstützungsdiensten erhöht, die speziell auf die besonderen Bedürfnisse von Frauen zugeschnitten sind.
Als Reaktion auf diese Nachfrage haben auf die psychische Gesundheit von Frauen spezialisierte Unternehmen die Möglichkeit, eine Reihe von Lösungen zu entwickeln und anzubieten, die auf die Verbesserung des psychischen Wohlbefindens und die Behandlung psychischer Störungen bei Frauen abzielen.
Mit digitalen Tools für die psychische Gesundheit und auf die spezifischen Bedürfnisse von Frauen zugeschnittenen Unterstützungsdiensten können Marktteilnehmer dazu beitragen, die psychische Gesundheit von Frauen in verschiedenen Gemeinschaften zu verbessern und ihre Lebensqualität zu steigern. Dies geschieht durch Investitionen in die Entwicklung innovativer Therapien. Die wachsende Anerkennung der Bedeutung der psychischen Gesundheit und des Wohlbefindens bei Frauen in Nordamerika und Europa bietet eine erhebliche Chance für das Marktwachstum.
Einschränkungen/Herausforderungen
- Nebenwirkungen im Zusammenhang mit bestimmten Produkten
In den letzten Jahren sind Bedenken hinsichtlich der Wirksamkeit und Sicherheit einer Reihe von Produkten für die Frauengesundheit aufgetaucht, wie etwa Körperpflegeartikel, medizinische Geräte und Medikamente. Verbraucher, Ärzte und Aufsichtsbehörden sind besorgt über die Nebenwirkungen dieser Produkte, zu denen Hormonersatzbehandlungen, Verhütungsmittel und Schönheitsoperationen gehören.
Die Einnahme von Medikamenten hat häufig negative Auswirkungen auf die Gesundheit von Frauen. Daher ist eine genaue Beobachtung, eine informierte Einwilligung und individuelle Behandlungspläne wichtig. Angehörige der Gesundheitsberufe müssen die Vor- und Nachteile von Arzneimitteltherapien sorgfältig abwägen und dabei die Präferenzen der Patientin sowie ihr Alter, ihre Krankengeschichte und Begleiterkrankungen berücksichtigen. Daher ist zu erwarten, dass die mit bestimmten Produkten verbundenen Nebenwirkungen das Marktwachstum bremsen.
- Auswirkungen von Umwelteinflüssen auf die reproduktive Gesundheit
Umweltbelastungen stellen aufgrund der Industrialisierung, Urbanisierung und des weit verbreiteten Einsatzes von Chemikalien in der Landwirtschaft, der Fertigung und bei Konsumgütern eine erhebliche Herausforderung für die reproduktive Gesundheit von Frauen in Nordamerika und Europa dar. Die Exposition gegenüber endokrin wirksamen Chemikalien (EDCs) wie BPA, Phthalaten und Pestiziden, die in Kunststoffen und Körperpflegeprodukten enthalten sind, kann zu Unfruchtbarkeit, Menstruationsstörungen und hormonellen Ungleichgewichten führen. Luftverschmutzung durch Industrieabgase und Fahrzeugabgase trägt zu negativen Schwangerschaftsergebnissen wie Frühgeburten und geringem Geburtsgewicht bei. Akteure auf dem Markt für Frauengesundheit können Risiken mindern und die reproduktive Gesundheit von Frauen in verschiedenen Gemeinschaften schützen. Dies kann durch Sensibilisierung, die Umsetzung vorbeugender Maßnahmen und das Eintreten für Maßnahmen zur Reduzierung der Umweltverschmutzung erreicht werden. Umweltbelastungen, die sich auf die reproduktive Gesundheit auswirken, stellen eine vielschichtige Herausforderung für das Marktwachstum dar.
Jüngste Entwicklungen
- Im November 2023 ging Lupin eine exklusive Partnerschaft mit Amman Pharmaceuticals Industries (Amman Pharma) ein, einem führenden Pharmahersteller mit Präsenz in der MENA-Region und auf verschiedenen globalen Märkten. Diese Zusammenarbeit umfasst die Marketing- und Vermarktungsrechte für Ranibizumab, ein Biosimilar von Lucentis. Diese strategische Partnerschaft ermöglicht es Lupin, neue Regionen zu erschließen und seine Marktpräsenz auszubauen, was letztlich die Position des Unternehmens in der Pharmaindustrie stärkt.
- Im Juli 2023 gab GSK plc. bekannt, dass die US-amerikanische Food and Drug Administration (FDA) Jemperli (Dostarlimab) als Einzelwirkstoff zur Behandlung erwachsener Patienten mit primär fortgeschrittenem oder rezidivierendem Endometriumkarzinom zugelassen hat, das eine hohe Mikrosatelliteninstabilität (MSI-H) oder einen Mangel an Mismatch-Reparatur (dMMR) aufweist, wie durch einen von der FDA zugelassenen Test festgestellt. Dies half dem Unternehmen, sein Produktangebot zu erweitern
- Im August 2022 gaben Myovant Sciences und Pfizer Inc. bekannt, dass die US-amerikanische Food and Drug Administration (FDA) MYFEMBREE (Relugolix 40 mg, Estradiol 1 mg und Norethindronacetat 0,5 mg) als einmal täglich einzunehmende Einzeltablettentherapie zur Behandlung mittelschwerer bis starker Schmerzen im Zusammenhang mit Endometriose bei Frauen vor der Menopause zugelassen hat. Die Behandlungsdauer kann bis zu 24 Monate betragen. Dies half dem Unternehmen, seine Produktpalette zu erweitern
- Im November 2020 hat Avion Pharmaceuticals (Tochtergesellschaft von Alora Pharmaceuticals, LLC), LLC, ein Spezialpharmaunternehmen, eine exklusive Lizenz- und Vermarktungsvereinbarung mit Aspen Pharma USA Inc. und Aspen Global Incorporated abgeschlossen. Diese Vereinbarung gewährt Avion die exklusiven Rechte zur Wiedereinführung der Cenestin-Tablette (synthetische konjugierte Östrogene, A), der einzigen pflanzlichen Mischung aus neun konjugierten Östrogenen
- Im Juni 2020 gab AbbVie Inc. in Zusammenarbeit mit Neurocrine Biosciences, Inc. bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die Zulassung für ORIAHNN (Elagolix-, Estradiol- und Norethisteronacetat-Kapseln; Elagolix-Kapseln) erteilt hat, was eine Behandlungsdauer von bis zu 24 Monaten ermöglicht. ORIAHNN ist die erste von der FDA zugelassene nicht-chirurgische, orale Behandlungsoption zur Behandlung starker Menstruationsblutungen im Zusammenhang mit Uterusmyomen bei Frauen vor der Menopause. Diese Zulassung erweitert das Portfolio des Unternehmens an Medikamenten für die Frauengesundheit und etabliert Neurocrine Biosciences als wichtigen Akteur auf diesem Gebiet.
Umfang des Marktes für Frauengesundheit in Nordamerika und Europa
Der nordamerikanische und europäische Markt für Frauengesundheit ist in sieben wichtige Segmente unterteilt, die auf Behandlung, Indikation, Verabreichungsart, Arzneimitteltyp, Pflegeart, Endverbraucher und Vertriebskanal basieren. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse wichtiger Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Behandlung
- Medikamente
- Gerät
Auf der Grundlage der Behandlung ist der nordamerikanische und europäische Markt für Frauengesundheit in Medikamente und Geräte segmentiert.
Anzeige
- Krebs
- Reproduktive Gesundheit
- Urologische Erkrankungen
- Schilddrüsenunterfunktion
- Postmenopausales Syndrom
- Sonstiges
Auf der Grundlage der Indikation ist der nordamerikanische und europäische Markt für Frauengesundheit in die Bereiche Krebs, reproduktive Gesundheit, urologische Erkrankungen, Schilddrüsenunterfunktion, Postmenopausensyndrom und Sonstiges segmentiert.
Liefermodus
- Rezept
- Über den Ladentisch
Auf Grundlage der Verabreichungsart ist der nordamerikanische und europäische Markt für Frauengesundheit in verschreibungspflichtige und rezeptfreie Arzneimittel segmentiert.
Arzneimitteltyp
- Gebrandmarkt
- Generisch
Auf der Grundlage des Arzneimitteltyps ist der nordamerikanische und europäische Markt für Frauengesundheit in Marken- und Generikaprodukte segmentiert.
Pflegetyp
- Allgemeine Gesundheitspflege und Wellness
- Schwangerschaft und Stillzeit
- Becken- und Gebärmuttergesundheit
- Sonstiges
Auf der Grundlage der Pflegeart ist der nordamerikanische und europäische Markt für Frauengesundheit in allgemeine Gesundheitspflege und Wellness, Schwangerschafts- und Stillpflege, Becken- und Gebärmuttergesundheit und Sonstiges segmentiert.
Endbenutzer
- Krankenhäuser und Kliniken
- Gynäkologische Zentren
- Einstellungen für die häusliche Pflege
- Forschungsinstitute
- Sonstiges
Auf der Grundlage des Endverbrauchers ist der nordamerikanische und europäische Markt für Frauengesundheit in Krankenhäuser und Kliniken, gynäkologische Zentren, Einrichtungen der häuslichen Pflege, Forschungsinstitute und andere unterteilt.
Vertriebskanal
- Direkte Ausschreibungen
- Einzelhandelsumsätze
- Online-Verkäufe
- Sonstiges
Auf der Grundlage der Vertriebskanäle ist der nordamerikanische und europäische Markt für Frauengesundheit in Direktausschreibungen, Einzelhandelsverkäufe, Online-Verkäufe und Sonstiges unterteilt.
Regionale Analyse/Einblicke zum nordamerikanischen und europäischen Frauengesundheitsmarkt
Der nordamerikanische und europäische Markt für Frauengesundheit ist in sieben wichtige Segmente unterteilt, die auf Behandlung, Indikation, Verabreichungsmodus, Arzneimitteltyp, Pflegeart, Endverbraucher und Vertriebskanal basieren.
Die vom Markt abgedeckten Länder sind die USA, Kanada, Mexiko, Deutschland, Frankreich, Italien, Spanien, die Schweiz, die Niederlande, Belgien, Russland, die Türkei, das Vereinigte Königreich und der Rest von Europa.
Nordamerika wird voraussichtlich den nordamerikanischen und europäischen Markt für Frauengesundheit dominieren, da infolge der F&E-Aktivitäten in der Region innovative Technologien entwickelt werden. Die USA werden voraussichtlich den nordamerikanischen Markt für Frauengesundheit dominieren, da dort eine fortschrittliche Gesundheitsinfrastruktur und technologische Innovationen im Bereich der Frauengesundheit vorhanden sind. Deutschland wird voraussichtlich den europäischen Markt für Frauengesundheit dominieren, da das Land auf dem internationalen Markt stark vertreten ist und über ein ausgedehntes Vertriebsnetz verfügt.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunktanalysen der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit regionaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken, die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.
Analyse der Marktanteile im Bereich Frauengesundheit in Nordamerika und Europa
Die Wettbewerbslandschaft des nordamerikanischen und europäischen Marktes für Frauengesundheit liefert Einzelheiten zu den Wettbewerbern. Die enthaltenen Einzelheiten umfassen Unternehmensübersicht, Unternehmensfinanzen, erzielten Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produkttestpipelines, Produktzulassungen, Patente, Produktbreite und -umfang, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen in Bezug auf den Markt.
Zu den wichtigsten Marktteilnehmern auf dem nordamerikanischen und europäischen Markt für Frauengesundheit zählen unter anderem Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc. und Pfizer Inc.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRY INSIGHTS
4.3.1 DRUG TREATMENT RATE IN MATURED MARKETS
4.3.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.3.3 PATIENT FLOW DIAGRAMS
4.3.4 KEY PRICING STRATEGIES
4.3.5 KEY ENROLLMENT STRATEGIES
4.4 PIPELINE ANALYSIS
4.5 PATENT DATA ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN
5.1.2 INNOVATIVE TECHNOLOGIES BEING DEVELOPED AS AN AFTERMATH OF R&D ACTIVITIES
5.1.3 GOVERNMENT INITIATIVES TO IMPROVE OVERALL HEALTH AND WELLBEING
5.1.4 CHANGING LIFESTYLES AND ENVIRONMENTAL FACTORS IMPACTING HEALTH
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH CERTAIN PRODUCTS
5.2.2 STRICT REGULATIONS IMPOSED BY THE REGULATORY AGENCIES
5.3 OPPORTUNITIES
5.3.1 INCREASING RECOGNITION FOR MENTAL HEALTH
5.3.2 GROWING AWARENESS AND ACCEPTANCE OF FERTILITY TREATMENTS
5.3.3 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.4 CHALLENGES
5.4.1 ENVIRONMENTAL EXPOSURE IMPACTING REPRODUCTIVE HEALTH
5.4.2 HIGH MATERNAL MORTALITY AND MORBIDITY
6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 DEVICE
7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CANCER
7.3 REPRODUCTIVE HEALTH
7.4 UROLOGICAL DISORDERS
7.5 HYPOTHYROIDISM
7.6 POST-MENOPAUSAL SYNDROME
7.7 OTHERS
8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE
8.1 OVERVIEW
8.2 GENERAL HEALTHCARE & WELLNESS
8.3 PREGNANCY & NURSING CARE
8.4 PELVIC & UTERINE HEALTHCARE
8.5 OTHERS
9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DELIVERY MODE
10.1 OVERVIEW
10.2 PRESCRIPTION
10.3 OVER THE COUNTER
11 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS AND CLINICS
11.3 GYNECOLOGY CENTERS
11.4 HOMECARE SETTING
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 U.K.
13.2.4 ITALY
13.2.5 RUSSIA
13.2.6 SPAIN
13.2.7 TURKEY
13.2.8 NETHERLANDS
13.2.9 SWITZERLAND
13.2.10 BELGIUM
13.2.11 REST OF EUROPE
14 NORTH AMERICA AND EUROPE WOMEN HEALTH MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.2 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 ABBVIE INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 GSK PLC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 LILLY
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 LUPIN
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NOVARTIS AG
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 NOVEN PHARMACEUTICALS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 PFIZER INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 VERTICAL PHARMACEUTICALS, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 VERU INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DEVICES
TABLE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DRUGS
TABLE 3 PATENT DATA (1/4)
TABLE 4 PATENT DATA (2/4)
TABLE 5 PATENT DATA (3/4)
TABLE 6 PATENT DATA (4/4)
TABLE 7 NORTH AMERICA WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 8 EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 EUROPE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 EUROPE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION
TABLE 18 EUROPE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 EUROPE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 EUROPE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 EUROPE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 EUROPE INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 EUROPE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 EUROPE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 EUROPE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 EUROPE CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 50 EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 EUROPE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 EUROPE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 58 EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 60 EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 EUROPE WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 66 U.S. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 67 U.S. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 U.S. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.S. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.S. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.S. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.S. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.S. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.S. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.S. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 U.S. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 U.S. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.S. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.S. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 U.S. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 88 U.S. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 90 U.S. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 U.S. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 94 U.S. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 95 CANADA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 96 CANADA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 CANADA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 CANADA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 CANADA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 CANADA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 CANADA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 CANADA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 CANADA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 CANADA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 CANADA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 CANADA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 CANADA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 CANADA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 CANADA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 112 CANADA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 CANADA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 117 CANADA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 CANADA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 CANADA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 123 CANADA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 124 MEXICO WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 MEXICO HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 MEXICO ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 MEXICO PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 MEXICO COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 MEXICO GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 MEXICO GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 MEXICO LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MEXICO NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MEXICO INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 MEXICO AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MEXICO DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 MEXICO INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 MEXICO WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 141 MEXICO CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MEXICO UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 MEXICO PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 MEXICO WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EUROPE WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 154 GERMANY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 GERMANY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 GERMANY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 GERMANY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 GERMANY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 GERMANY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 GERMANY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 GERMANY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 GERMANY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 GERMANY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 GERMANY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 GERMANY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 GERMANY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 GERMANY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 170 GERMANY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 171 GERMANY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 GERMANY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 GERMANY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 GERMANY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 175 GERMANY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 176 GERMANY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 177 GERMANY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 178 GERMANY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 GERMANY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 GERMANY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 GERMANY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 FRANCE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 FRANCE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 FRANCE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 FRANCE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 FRANCE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 FRANCE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 FRANCE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 FRANCE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 FRANCE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 193 FRANCE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 FRANCE INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 FRANCE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 FRANCE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 FRANCE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 FRANCE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 200 FRANCE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 FRANCE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 FRANCE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 FRANCE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 FRANCE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 205 FRANCE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 206 FRANCE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 207 FRANCE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 FRANCE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 FRANCE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 FRANCE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 FRANCE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 U.K. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 U.K. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 U.K. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 215 U.K. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 U.K. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 U.K. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 U.K. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 U.K. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 U.K. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 U.K. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 U.K. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 U.K. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 225 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 U.K. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 227 U.K. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 U.K. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 229 U.K. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 U.K. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 U.K. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 232 U.K. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 U.K. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 234 U.K. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 235 U.K. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 236 U.K. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 U.K. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 U.K. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 U.K. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 240 U.K. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 241 ITALY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 ITALY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 ITALY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 ITALY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 245 ITALY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 ITALY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 ITALY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 ITALY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 ITALY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 ITALY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 252 ITALY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 ITALY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ITALY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ITALY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 ITALY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 258 ITALY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 ITALY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 ITALY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 ITALY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 ITALY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 263 ITALY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 264 ITALY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 265 ITALY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ITALY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ITALY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ITALY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ITALY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 RUSSIA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 271 RUSSIA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 RUSSIA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 RUSSIA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 RUSSIA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 RUSSIA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 RUSSIA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 RUSSIA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 RUSSIA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 RUSSIA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 RUSSIA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 RUSSIA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 RUSSIA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 286 RUSSIA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 287 RUSSIA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 RUSSIA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 RUSSIA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 RUSSIA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 RUSSIA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 292 RUSSIA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 293 RUSSIA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 294 RUSSIA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 RUSSIA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 296 RUSSIA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 RUSSIA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 298 RUSSIA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 299 SPAIN WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 300 SPAIN DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 SPAIN HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 302 SPAIN ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 SPAIN PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 304 SPAIN COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 SPAIN GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 SPAIN GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 307 SPAIN LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 SPAIN NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 310 SPAIN INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 311 SPAIN AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 SPAIN DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 SPAIN INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 315 SPAIN WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 316 SPAIN CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 SPAIN REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 SPAIN UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 319 SPAIN OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 320 SPAIN WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 321 SPAIN WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 322 SPAIN WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 323 SPAIN GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 324 SPAIN PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 SPAIN PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 SPAIN WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 327 SPAIN WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 328 TURKEY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 329 TURKEY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 330 TURKEY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 331 TURKEY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 332 TURKEY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 333 TURKEY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 TURKEY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 TURKEY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 336 TURKEY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 337 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 338 TURKEY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 339 TURKEY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 340 TURKEY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 341 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 TURKEY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 TURKEY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 344 TURKEY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 345 TURKEY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 TURKEY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 347 TURKEY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 348 TURKEY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 349 TURKEY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 350 TURKEY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 351 TURKEY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 352 TURKEY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 353 TURKEY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 354 TURKEY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 355 TURKEY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 TURKEY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 NETHERLANDS WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 358 NETHERLANDS DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 359 NETHERLANDS HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 NETHERLANDS ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 NETHERLANDS PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 362 NETHERLANDS COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 363 NETHERLANDS GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 365 NETHERLANDS LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 366 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 367 NETHERLANDS NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 368 NETHERLANDS INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 NETHERLANDS AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 371 NETHERLANDS DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 372 NETHERLANDS INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 373 NETHERLANDS WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 374 NETHERLANDS CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 375 NETHERLANDS REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 376 NETHERLANDS UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 NETHERLANDS OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 NETHERLANDS WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 379 NETHERLANDS WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 380 NETHERLANDS WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 381 NETHERLANDS GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 382 NETHERLANDS PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 383 NETHERLANDS PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 384 NETHERLANDS WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 385 NETHERLANDS WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 386 SWITZERLAND WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 387 SWITZERLAND DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 388 SWITZERLAND HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 389 SWITZERLAND ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 390 SWITZERLAND PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 391 SWITZERLAND COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 392 SWITZERLAND GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 393 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 SWITZERLAND LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 396 SWITZERLAND NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 397 SWITZERLAND INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 SWITZERLAND AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 399 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 400 SWITZERLAND DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 401 SWITZERLAND INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 402 SWITZERLAND WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 403 SWITZERLAND CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 SWITZERLAND REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 405 SWITZERLAND UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 406 SWITZERLAND OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 407 SWITZERLAND WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 408 SWITZERLAND WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 409 SWITZERLAND WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 410 SWITZERLAND GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SWITZERLAND PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SWITZERLAND PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 413 SWITZERLAND WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 414 SWITZERLAND WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 415 BELGIUM WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 416 BELGIUM DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 417 BELGIUM HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 418 BELGIUM ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 419 BELGIUM PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 BELGIUM COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 BELGIUM GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 422 BELGIUM GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 423 BELGIUM LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 424 BELGIUM GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 425 BELGIUM NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 426 BELGIUM INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 427 BELGIUM AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 BELGIUM DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 430 BELGIUM INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 431 BELGIUM WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 432 BELGIUM CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 433 BELGIUM REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 434 BELGIUM UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 435 BELGIUM OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 436 BELGIUM WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 437 BELGIUM WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 438 BELGIUM WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 439 BELGIUM GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 440 BELGIUM PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 441 BELGIUM PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 442 BELGIUM WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 444 REST OF EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET
FIGURE 14 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 15 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 16 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 17 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 19 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 21 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 23 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 24 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 27 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 29 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 31 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 32 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 34 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 35 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 38 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 39 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 40 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 42 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 43 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 45 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 47 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 48 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 49 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 50 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 51 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 53 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 54 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 55 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 56 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 57 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 59 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 60 EUROPE WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 61 EUROPE WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 63 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 64 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 65 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 66 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 67 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 68 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 69 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 NORTH AMERICA WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 71 EUROPE WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 72 NORTH AMERICA WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
FIGURE 73 EUROPE WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
